Syschem India posts ₹1.67 cr net loss in Q1FY26 as expenses rise
Syschem (India) Limited posted a standalone net loss of ₹166.80 lakh in Q1FY26, compared to a profit of ₹167.35 lakh in Q1FY25. Revenue remained flat at ₹1,259.48 lakh, but total expenses increased to ₹12,744.70 lakh. The Board also disclosed the forfeiture of ₹39.17 lakh from lapsed convertible warrants.

*this image is generated using AI for illustrative purposes only.
Syschem (India) Limited reported a standalone net loss of ₹166.80 lakh for the quarter ended June 30, 2026, marking a significant reversal from the ₹167.35 lakh profit recorded in the same period of FY25. The deterioration in profitability was driven by a 1.9% increase in total expenses to ₹12,744.70 lakh, despite revenue from operations remaining largely flat at ₹1,259.48 lakh against ₹1,267.58 lakh in Q1FY25. This operational pressure resulted in a pre-tax loss of ₹145.24 lakh, compared to a pre-tax profit of ₹167.35 lakh in the prior year quarter.
The Board of Directors approved these unaudited financial results on August 04, 2026. The statutory auditor, Stav & Co., issued a limited review report on the financial statements in accordance with Standard on Review Engagement (SRE) 2410 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Additionally, the Board addressed the forfeiture of upfront consideration linked to lapsed convertible warrants, impacting the company’s capital structure disclosures.
Financial Performance Overview
The following table highlights the key financial metrics for Syschem (India) Limited for the quarter ended June 30, 2026:
| Metric | Q1FY26 (₹ Lakh) | Q1FY25 (₹ Lakh) | Change |
|---|---|---|---|
| Revenue from Operations | 1,259.48 | 1,267.58 | -0.6% |
| Total Income | 1,259.95 | 1,267.64 | -0.6% |
| Total Expenses | 12,744.70 | 12,509.00 | +1.9% |
| Profit Before Tax | -145.24 | 167.35 | Turned Negative |
| Net Profit/Loss | -166.80 | 167.35 | Turned Negative |
| EPS (Basic/Diluted) | -0.31 | 0.38 | Declined |
Note: Figures are in ₹ Lakh unless otherwise specified.
Warrant Lapse and Forfeiture
In a separate development, the Board disclosed the lapse of convertible warrants allotted on a preferential basis on February 04, 2025. The company had allotted 16.7 million warrants, entitling holders to convert them into equity shares within 18 months. The final date for exercise was August 03, 2026.
As allottees failed to exercise their conversion options within the stipulated period, 3.19 million warrants lapsed. Consequently, the company forfeited the upfront amount of ₹39.17 lakh (₹3,91,69,375), which represented 25% of the issue price received at the time of allotment. This forfeiture was disclosed under Regulation 30 of the SEBI (LODR) Regulations, 2015. The specific allottees who failed to convert included Dinesh Jagdishchandra Khokhani, Mahesh J Khokhani, and Mehul Jagadishchandra Khokhani.
What the Numbers Show
The shift from profitability to a net loss in Q1FY26 was driven by an expansion in total expenses rather than a decline in top-line revenue. While gross revenue remained stable year-on-year, total expenses rose by approximately 1.9%, primarily due to higher other expenses (₹577.02 lakh vs ₹134.92 lakh) and employee benefits (₹404.20 lakh vs ₹191.34 lakh). Other income saw a significant increase to ₹4.66 lakh from ₹0.52 lakh in the previous year, but this was insufficient to offset the operational cost pressures. The basic earnings per share fell to -₹0.31 from ₹0.38 in Q1FY25, reflecting the impact of the net loss on shareholder value for the period.
Historical Stock Returns for Syschem
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +4.47% | +0.85% | -27.46% | -35.56% | -38.71% | +286.25% |
What specific operational or strategic measures is Syschem implementing to curb the 1.9% rise in total expenses and restore profitability in subsequent quarters?
How will the forfeiture of ₹39.17 lakh from lapsed convertible warrants impact the company's future capital raising strategies or relationships with existing investors?
Given the sharp increase in 'other expenses' and employee benefits, are there indications of restructuring costs or new hiring initiatives that might persist in Q2FY26?


































